清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and safety of Shenbai Granules for recurrent colorectal adenoma: A multicenter randomized controlled trial

结直肠腺瘤 随机对照试验 胃肠病学 医学 腺瘤 内科学 结直肠癌 肿瘤科 癌症
作者
Mingxin Ni,Y. Zhang,Zhenzhen Sun,Qing Zhou,Jun Xiao,Beiping Zhang,Jiang Lin,Biao Gong,Fengbin Liu,Fandong Meng,Guoyin Zheng,Yan Wang,Limei Gu,Liu Li,Liu Li,Weixing Shen,Yugen Chen,Yanmei Liu,Ling Li,Ling Li
出处
期刊:Phytomedicine [Elsevier BV]
卷期号:127: 155496-155496 被引量:18
标识
DOI:10.1016/j.phymed.2024.155496
摘要

BACKGROUND: Colorectal adenoma is benign glandular tumor of colon, the precursor of colorectal cancer. But no pharmaceutical medication is currently available to treat and prevent adenomas. PURPOSE: To evaluate efficacy of Shenbai Granules, an herbal medicine formula, in reducing the recurrence of adenomas. STUDY DESIGN: This multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted by eight hospitals in China. METHODS: Patients who had received complete polypectomy and were diagnosed with adenomas within the recent 6 months were randomly assigned (1:1) to receive either Shenbai granules or placebo twice a day for 6 months. An annual colonoscopy was performed during the 2-year follow-up period. The primary outcome was the proportion of patients with at least one adenoma detected in the modified intention-to-treat (mITT) population during follow-up for 2 years. The secondary outcomes were the proportion of patients with sessile serrated lesions and other specified polypoid lesions. The data were analyzed using logistic regression. RESULTS: Among 400 randomized patients, 336 were included in the mITT population. We found significant differences between treatment and placebo groups in the proportion of patients with at least one recurrent adenoma (42.5 % vs. 58.6 %; OR, 0.47; 95 % CI, 0.29-0.74; p = 0.001) and sessile serrated lesion (1.8 % vs. 8.3 %; OR, 0.20; 95 % CI, 0.06-0.72; p = 0.01). There was no significant difference in the proportion of patients developing polypoid lesions (70.7 % vs. 77.5 %; OR, 1.43; 95 % CI, 0.88-2.34; p = 0.15) or high-risk adenomas (9.0 % vs. 13.6 %; OR, 0.63; 95 % CI, 0.32-1.25; p = 0.18). CONCLUSION: Shenbai Granules significantly reduced the recurrence of adenomas, indicating that they could be an effective option for adenomas. Future studies should investigate its effects in larger patient populations and explore its mechanism of action to provide more comprehensive evidence for the use of Shenbai Granules in adenoma treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Turing完成签到,获得积分10
2秒前
苏亚婷完成签到,获得积分10
4秒前
排骨大王完成签到 ,获得积分10
9秒前
叁月二完成签到 ,获得积分10
10秒前
白桃战士完成签到,获得积分10
11秒前
gzhy完成签到,获得积分10
20秒前
幽默的破茧完成签到 ,获得积分10
21秒前
善良的梦桃完成签到,获得积分20
21秒前
t铁核桃1985完成签到 ,获得积分0
26秒前
27秒前
30秒前
NexusExplorer应助科研通管家采纳,获得10
30秒前
cdercder应助科研通管家采纳,获得10
30秒前
研友_LmVygn完成签到 ,获得积分10
33秒前
34秒前
Rocky完成签到 ,获得积分10
37秒前
桓某人发布了新的文献求助10
40秒前
Alvin完成签到 ,获得积分10
44秒前
年轻花卷完成签到,获得积分10
1分钟前
zhangnan完成签到 ,获得积分10
1分钟前
腼腆的山兰完成签到 ,获得积分10
1分钟前
奋斗的小质关注了科研通微信公众号
1分钟前
1分钟前
Ray完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
2分钟前
tcy完成签到,获得积分10
2分钟前
古炮发布了新的文献求助50
2分钟前
2分钟前
Karl完成签到,获得积分10
2分钟前
Copyright应助科研通管家采纳,获得10
2分钟前
lingling完成签到 ,获得积分10
2分钟前
2分钟前
整齐半青完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
Henry完成签到,获得积分10
3分钟前
顾君如完成签到,获得积分10
3分钟前
希望天下0贩的0应助古炮采纳,获得30
3分钟前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Arthritis and Related Conditions, An Issue of Orthopedic Clinics 1000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7290500
求助须知:如何正确求助?哪些是违规求助? 8909683
关于积分的说明 18857008
捐赠科研通 6957940
什么是DOI,文献DOI怎么找? 3209151
关于科研通互助平台的介绍 2378910
邀请新用户注册赠送积分活动 2184884